Clinical Trials Browser

Triple Negative Breast Neoplasms

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Colorectal Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Recurrence, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms, Triple Negative Breast Neoplasms

Recurrence, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Multiple Myeloma, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Clinical Trials

ONSET

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

ADAPT-TN-IV

Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

CT-202

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

RESTORE

QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.

Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.

PLANET

EINSTEIN-TNBC

Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer

BERLIN

EPPIL

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

DUNP19

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

RECLAIM

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

NoCUT-BC

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

POLARIS

WISH-OMICHIR

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Fzp-MA-TNBC

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

TREND-02

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

LOGIC

Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

ALTER

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

TEBICA003 TNBC

SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer

KEY-MELT